The Metabolic Fitness Gene That Cuts Disease Risk by 60%

The Discovery

What Is FNIP1?

FNIP1 (Folliculin Interacting Protein 1) is a gene that tells your body to store energy rather than burn it. For our ancestors facing famine, this was survival. In our calorie-rich modern world, it drives obesity, fatty liver, and metabolic disease.

Regeneron scientists analyzed the exomes of over one million people and found that those born with a loss-of-function mutation in FNIP1 (about 1 in 7,000) had dramatically better metabolic profiles.

What the carriers had:

1. Lower liver fat and visceral fat
2. Better insulin sensitivity and glycemic control
3. Lower triglycerides and ApoB
4. More favorable fat distribution (less belly, more subcutaneous)
5. Higher lean body mass percentage
6. ~60% lower odds of cardiometabolic disease

“The FNIP1 pathway can be considered a ‘metabolic brake,’ curbing the consumption of energy so that calories can be saved for a rainy day. This happened all the time over millennia of human evolution but almost never happens in the modern calorie-rich environment.”
— Dr. Luca Andrea Lotta, Regeneron Genetics Center

Want to know your TG:HDL ratio and metabolic fitness markers? A longevity panel maps where you stand.

The Mechanism

AMPK: Your Cellular Energy Switch

FNIP1 works by suppressing AMPK — your cell’s master energy sensor. When FNIP1 is active, AMPK stays quiet and your body stores fat. When FNIP1 is inhibited, AMPK activates and triggers:

This is exactly what exercise does. When you work out, AMPK phosphorylates FNIP1 and effectively “switches it off.” The question is: what else can do this?

Interventions

What Else Can Release the Brake?

If FNIP1 is the brake and AMPK is the accelerator, several interventions can shift the balance. None are a magic bullet alone — but combined with monitoring, they form a protocol.

Exercise

Strongest evidence

Directly phosphorylates FNIP1 via AMPK. Muscle FNIP1 expression is downregulated by training. This is the gold standard.

Malik et al., Science 2023; Science Advances 2024

Metformin

Strong evidence

Well-established AMPK activator. Used for diabetes, being studied in the TAME trial for aging. Mimics some exercise benefits on the FNIP1 pathway.

TAME Trial; Hardie, Curr Opin Cell Biol 2015

Berberine

Moderate evidence

Activates AMPK via lysosomal pathway. Human trials show consistent metabolic benefits. A natural compound with metformin-like effects.

Frontiers in Pharmacology 2023; Wang et al. 2026

Tesamorelin

Clinical trials

FDA-approved GHRH analog. Reduces visceral fat and liver fat in clinical trials. Achieves similar metabolic endpoints through GH-mediated lipolysis rather than direct AMPK activation.

Stanley et al., JAMA 2014; Lancet HIV 2019; NCT03375788

Mitochondrial Targeting

Feeding the Powerhouses Directly

If FNIP1 inhibition unleashes mitochondrial biogenesis, these compounds support the mitochondria themselves — clearing damaged ones, stabilizing membranes, and fueling the electron transport chain. They work downstream of AMPK activation.

MOTS-c

Strong preclinical + human data

A mitochondrial-derived peptide that directly activates AMPK — the same pathway FNIP1 loss-of-function triggers. Acts as a true exercise mimetic: increases glucose uptake into skeletal muscle, promotes fat oxidation, and improves insulin sensitivity.

Lee et al., Cell Metabolism 2015; Zheng et al., 2023; Yang et al., 2021

SS-31 (Elamipretide)

FDA-approved (rare disease)

Targets cardiolipin in the inner mitochondrial membrane, stabilizing electron transport and reducing ROS. FDA-approved for Barth syndrome (2025). Clinical trials show improved mitochondrial ATP production in older adults after a single dose.

Roshanravan et al., PLoS One 2021; FDA approval Oct 2025; Szeto, 2018

Urolithin A (Mitopure)

Human clinical trials

Activates mitophagy — clearing damaged mitochondria so new ones can be built. Also activates AMPK. Human trials show ~12% improvement in muscle strength after 4 months. Commercially available as Timeline (Amazentis).

Ryu et al., Nature Medicine 2016; Andreux et al., 2019; Liu et al., 2022

CoQ10 / Ubiquinol

Established supplement

Essential electron carrier in the mitochondrial respiratory chain. Levels decline with age and statin use. Supports ATP production and reduces oxidative damage. Ubiquinol (reduced form) has better bioavailability.

Hernández-Camacho et al., 2018; Littarru & Tiano, 2010

The key insight: AMPK activators (exercise, metformin, MOTS-c) tell your cells tobuild more mitochondria. Mitochondrial-targeted compounds (SS-31, urolithin A, CoQ10) help those mitochondria function better. The combination is more powerful than either alone.

Exercise is the gold standard. But when it's not enough — or hormones are declining — we have options.

The Hormone Connection

When Hormones Decline, the Brake Gets Stuck

Testosterone directly increases AMPK expression and phosphorylation. When levels decline inandropause (men) or menopause (women), AMPK activity drops — and the FNIP1 “brake” tightens. The result: visceral fat accumulation, insulin resistance, mitochondrial dysfunction.

The Evidence

Testosterone → AMPK. Ghanim et al. (JCEM 2020): Testosterone replacement increases AMPK expression and phosphorylation in men with hypogonadism and type 2 diabetes. The effect was absent in eugonadal controls — meaning TRT restores what was lost, not artificially elevates.

Estrogen → Mitochondria

Estrogen decline during menopause disrupts mitochondrial homeostasis, reduces bioenergetic capacity, and accelerates age-related metabolic dysfunction (Yu et al. 2025; Bynum et al. 2026). HRT can partially restore mitochondrial function.

5-Year TRT Data. Long-term testosterone therapy in hypogonadal men: reduced waist circumference by 8.5 cm, body weight by 15 kg, improved insulin sensitivity, and reduced metabolic syndrome markers.

This is why FNIP1 pathway activity may be one of the things we want to track as patients age — to see when it has declined enough to consider hormone replacement therapy as part of a broader metabolic optimization strategy.

The Nuance

This Will Not Be One Peptide

Biology does not work in isolation. Mimicking FNIP1 loss-of-function will likely require amulti-modal approach — and each intervention introduces trade-offs that need monitoring.

Testosterone replacement. Monitor: Lipid panel (HDL may decrease), PSA, hematocrit, estradiol

2024 Cedars-Sinai data confirms no increased cardiovascular risk when properly monitored

Metformin

Monitor: B12 levels, GI tolerance, lactate (rare)

May blunt some exercise adaptations — timing matters

Tesamorelin

Monitor: Fasting glucose, IGF-1 levels, injection site reactions

Expensive; primarily studied in HIV lipodystrophy, expanding to general NAFLD

Berberine

Monitor: Liver enzymes, drug interactions (CYP3A4)

Natural compound but still pharmacologically active

The point is not to find one drug that replaces a gene. The point is to measure, intervene with the right combination, and then prove you actually changed the markers.

— Dr. Dusan Sajic, MD, PhD

The New Era

We Are Entering True Aging Reversal

This FNIP1 study is not an isolated finding. It sits within a wave of breakthroughs that are moving aging from an inevitable decline to a modifiable condition:

Life Biosciences: First human epigenetic reprogramming injection

June 2026

FDA-cleared trial to reverse age-related vision loss by making old cells act younger.

Regeneron: FNIP1 as therapeutic target

August 2026

Pursuing siRNA and genetic medicines to silence FNIP1 in humans. 23 of 59 identified genes already have drugs in development.

TAME Trial: Metformin for aging

Ongoing

First FDA-recognized trial targeting aging itself as a condition, not just individual diseases.

Altos Labs: Partial cellular reprogramming

Active research

Billions invested in understanding how to safely reset cellular age without causing cancer.

We are no longer guessing. We are measuring, intervening, and proving — at the molecular level — that we changed something. That is the future of medicine. And it is available now.

Our Approach

We Measure What This Study Measured

You do not need to be born with a rare mutation. You need to measure where you stand, intervene with the right combination, andprove you changed it.

1. TG:HDL Ratio. The exact biomarker used in this study to identify metabolic fitness
2. Liver Fat (MRI-PDFF). Direct measure of hepatic steatosis — what FNIP1 loss-of-function reduces
3. Visceral Fat (DEXA). The dangerous fat around organs that AMPK activation burns
4. Fasting Insulin / HOMA-IR. Insulin sensitivity — improved in FNIP1 carriers

5

Testosterone / Estradiol

Hormone levels that directly regulate AMPK expression

1. hs-CRP / IL-6. Inflammatory markers that worsen when the metabolic brake is stuck
2. TruAge (Epigenetic Clock). Biological age — the ultimate outcome measure
3. PAOT (Oxidative Reserves). Antioxidant capacity that supports mitochondrial function

We are constantly refining this. As new research emerges — like this FNIP1 study — we add markers, adjust protocols, and re-test. The goal is not just visual improvement butmolecular improvement that you can measure.

Longevity & concierge medicine

FNIP1 & Metabolic Fitness: FAQ

Straight answers on the metabolic brake gene, AMPK, Tesamorelin, hormone therapy, and what you can do now.

Sources & References

1. Hindy G, Adam RC, et al. FNIP1 variants are associated with favourable metabolism in 1 million humans. Nature. 2026.
2. Malik N, et al. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science. 2023;380:eabj5559.
3. AMPK phosphorylation of FNIP1 (S220) controls mitochondrial function and muscle fuel utilization during exercise. Science Advances. 2024.
4. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA. 2014;312(4):380-389.
5. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV. 2019;6(12):e821-e830.
6. Ghanim H, et al. Testosterone increases the expression and phosphorylation of AMP kinase α in men with hypogonadism and type 2 diabetes. JCEM. 2020;105(4):1169-1178.
7. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM. 2023;389:107-117. (TRAVERSE Trial)
8. Life Biosciences. First patient dosed with cellular reprogramming injection. June 2026.
9. Shenhar B, et al. Heritability of intrinsic human life span is about 50%. Science. 2026;391(6784):504-510.
10. FNIP1 regulates adipocyte browning and systemic glucose homeostasis. J Exp Med. 2022;219(5):e20212491.
11. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
12. Roshanravan B, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide. PLoS One. 2021;16(7):e0253849.
13. Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1:595-603.